Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2709Lung Neoplasms 2267Small Cell Lung Carcinoma 452Breast Neoplasms 394Neoplasms 348Colorectal Neoplasms 245Ovarian Neoplasms 208Pancreatic Neoplasms 196Melanoma 196Prostatic Neoplasms 187Adenocarcinoma of Lung 184Neoplasm Metastasis 177Head and Neck Neoplasms 175Mesothelioma, Malignant 152Esophageal Neoplasms 144Carcinoma, Renal Cell 142Stomach Neoplasms 141Colonic Neoplasms 138Urinary Bladder Neoplasms 124Mesothelioma 121Squamous Cell Carcinoma of Head and Neck 115Uterine Cervical Neoplasms 97Sarcoma 86Brain Neoplasms 86Kidney Neoplasms 82Carcinoma, Hepatocellular 71Liver Neoplasms 68Adenocarcinoma, Bronchiolo-Alveolar 68Rectal Neoplasms 64Pleural Effusion, Malignant 64

Interventions

seribantumab 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lethal Congenital Contracture Syndrome 2 × Thoracic × Clear all
NCT00994123 2016-08-22

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Merrimack Pharmaceuticals

Phase 1/2 Completed
162 enrolled 11 charts
Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡